Outlook Therapeutics · ONS-5010 · Jan – Jun 2026

What happened after the FDA's December 2025 letter?

Informal meetings, a Type A meeting, a formal dispute resolution request, an appeal Outlook says was granted, and a Class 1 resubmission on June 1, 2026, where this record ends.

EphemerisX Research · Published October 7, 2026 · 6 source documents · 1 min read

Short answer

Outlook met the FDA informally, requested a Type A meeting (held March 2, 2026), then filed a formal dispute resolution request that the FDA accepted. On May 26 it reported that the appeal had been granted, and on June 1 it resubmitted the application as a Class 1 resubmission, with a decision expected within 60 days. The record ends there.

What the evidence shows

February 2026: Prior to submitting the Type A meeting request, Outlook Therapeutics conducted informal meetings with the FDA to discuss the CRL 8-K · Feb 11, 2026. March 2026: we reported that we had received a third Complete Response Letter 8-K · Mar 16, 2026, and the FDA did not indicate in the CRL what type of confirmatory evidence would be acceptable 8-K · Mar 16, 2026.

April 2026: a formal Type A meeting on March 2, 2026, which led to the submission of the FDRR and associated meeting 8-K · Apr 7, 2026; The FDA has accepted the FDRR and has granted a meeting with the deciding official to be conducted in April 2026 8-K · Apr 7, 2026. On April 21 the company said it had completed its Federal Dispute Resolution meeting 8-K · Apr 21, 2026 with the Office of New Drugs at the U.S. Food and Drug Administration (FDA) 8-K · Apr 21, 2026.

May 26, 2026: the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND) 8-K · May 26, 2026. June 1, 2026: today announced the resubmission of its Biologics License Application (BLA) 8-K · Jun 1, 2026, a Class 1 resubmission with a PDUFA date and decision expected within 60 days of FDA’s receipt of the resubmission 8-K · Jun 1, 2026.

Not in this record: an FDA action on the June 2026 resubmission. On what the appeal decided: How did evidence the FDA said did not alter its conclusion come to establish substantial evidence?

Follow the thread

What did Outlook say came out of its September 2025 meeting with the FDA?“Aligned”, then “unexpected”
How did evidence the FDA said did not alter its conclusion come to establish substantial evidence?From the division to the Office of New Drugs
Did the FDA ask Outlook for another clinical trial, or for confirmatory evidence?March 2026: the “third” letter

This investigation connects to

What happens after a second FDA Complete Response Letter?Cross-investigation · Divergent outcome · with Aldeyra Therapeutics, CorMedix, Replimune, Verrica Pharmaceuticals
How did two programs move forward after repeat FDA letters without running a new trial?Cross-investigation · Comparable evidence · with Replimune
What is a Class 1 or Class 2 resubmission, and how did each play out in these records?Cross-investigation · Regulatory pathway · with Aldeyra Therapeutics, CorMedix, Replimune

The documents, by date

The passages quoted

Outlook Therapeutics Form 8-K, filed February 11, 2026

The CRL identified a single deficiency based on a purported lack of substantial evidence of effectiveness, and recommended submission of additional confirmatory evidence. Outlook Therapeutics believes this determination is inconsistent with the totality of evidence submitted in the BLA, including data from an adequate and well-controlled study and confirmatory evidence of effectiveness. Based on prior discussions with the FDA in September 2025, during which Outlook Therapeutics understood that it had aligned with FDA on the requirements for resubmission of the BLA, the issuance of an additional CRL was unexpected. Prior to submitting the Type A meeting request, Outlook Therapeutics conducted informal meetings with the FDA to discuss the CRL.

Open at the source →

Outlook Therapeutics Form 8-K, filed March 16, 2026

Moreover, on December 31, 2025, we reported that we had received a third Complete Response Letter, or CRL, with respect to our Biologics License Application, or BLA, for ONS-5010, and the U.S. Food and Drug Administration, or FDA, has again recommended that confirmatory evidence of efficacy be submitted to support the application. However, the FDA did not indicate in the CRL what type of confirmatory evidence would be acceptable, and it is possible that we may need to conduct additional clinical and/or non-clinical studies of ONS-5010 in order to satisfy the FDA’s requirements

Open at the source →

Outlook Therapeutics Form 8-K, filed April 7, 2026

today announced that it submitted a formal dispute resolution request (FDRR) to the U.S. Food and Drug Administration (FDA) as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration. The FDA has accepted the FDRR and has granted a meeting with the deciding official to be conducted in April 2026.

Open at the source →

Outlook Therapeutics Form 8-K, filed April 7, 2026

Subsequent to receiving the CRL in December 2025, Outlook Therapeutics has engaged with the FDA on multiple occasions, including a formal Type A meeting on March 2, 2026, which led to the submission of the FDRR and associated meeting.

Open at the source →

Outlook Therapeutics Form 8-K, filed April 21, 2026

today announced that it has completed its Federal Dispute Resolution meeting w ith the Office of New Drugs at the U.S. Food and Drug Administration (FDA). The meeting was conducted as part of the Company’s ongoing efforts to seek alignment with the FDA regarding the regulatory pathway for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) and as a follow-up to its recent Type A meeting with the Division of Ophthalmology and Office of Specialty Medicine regarding the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration

Open at the source →

Outlook Therapeutics Form 8-K, filed May 26, 2026

today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND). The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD). As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) in June 2026.

Open at the source →

Outlook Therapeutics Form 8-K, filed June 1, 2026

The FDR decision directed the Division of Ophthalmology and Office of Specialty Medicine to work with Outlook Therapeutics to focus on reach ing an agreement on final product labeling. Additionally, as indicated in the formal decision, this will be a Class 1 resubmission with a PDUFA date and decision expected within 60 days of FDA’s receipt of the resubmission.

Open at the source →

Outlook Therapeutics Form 8-K, filed June 1, 2026

today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD).

Open at the source →